Boura Iro, Poplawska-Domaszewicz Karolina, Limbachiya Naomi, Trivedi Dhaval, Batzu Lucia, Chaudhuri Kallol Ray
School of Medicine, University of Crete, Heraklion, Greece; Parkinson's Foundation Centre of Excellence, King's College Hospital, London, UK.
Parkinson's Foundation Centre of Excellence, King's College Hospital, London, UK; Department of Neurology, Poznan University of Medical Sciences, Poznan, Poland.
Neurol Clin. 2025 May;43(2):209-228. doi: 10.1016/j.ncl.2024.12.004. Epub 2025 Jan 22.
Early observations of specific nonmotor and subtle motor symptoms preceding clinical diagnosis of Parkinson's disease (PD) have paved the way for prodromal PD research, significantly propelling our understanding of early, subclinical stages of neurodegeneration. Prodromal PD has emerged as a complex concept with some researchers suggesting that the period before PD onset is divided into the "at-risk," "preclinical," and "prodromal" phases. Advances in genetic, imaging, laboratory, and digital technologies have enabled the identification of pathophysiological patterns and the potential development of diagnostic, progressive, and therapeutic biomarkers, which could lead to early PD detection and intervention.
在帕金森病(PD)临床诊断之前对特定非运动和细微运动症状的早期观察为前驱期PD研究铺平了道路,极大地推动了我们对神经退行性变早期亚临床阶段的理解。前驱期PD已成为一个复杂的概念,一些研究人员认为,PD发病前的时期可分为“风险期”“临床前期”和“前驱期”。基因、成像、实验室和数字技术的进步使病理生理模式得以识别,以及诊断、进展和治疗生物标志物的潜在开发成为可能,这可能会实现PD的早期检测和干预。